With a strong vision, albeit limited experience and knowledge of the pharmaceutical industry, Birgitte and Hans Bøgh-Sørensen has grown Orifarm from a “two-owners-one-employee” company to an international organization with offices across Europe and in the United States.
Starting out with a strong entrepreneurial mission to make high-quality pharmaceuticals a better deal for patients, society, and Orifarm, Birgitte and Hans Bøgh-Sørensen have grown Orifarm from a small danish company in 1994 into an impressive international organization employing more than 2,300 colleagues.
Orifarm is a family-owned company. The company was founded in Odense, Denmark, in 1994 by Birgitte and Hans Bøgh-Sørensen. Today, Orifarm is owned by the founding couple and their three grown-up children, Christian, Anne-Charlotte, and Andreas Bøgh-Sørensen. Nearly 30 years after the foundation of Orifarm, owners Birgitte and Hans Bøgh-Sørensen still remain heavily involved in the continuous long-term development of Orifarm.
In January 2019, Hans Bøgh-Sørensen stepped down as CEO and handed over control of the daily business to Group CEO Erik Sandberg.
However, Hans Bøgh-Sørensen remained a member of the Board of Directors, and in August 2020, he took over as Chairman of the Board of Directors of Orifarm Group.
Having appointed a new CEO to control daily business, Hans Bøgh-Sørensen remains a member of the Board of Directors, and in August 2020, he took over as Chairman of the Board of Directors of Orifarm Group.
1994: Orifarm was founded by Birgitte and Hans Bøgh-Sørensen.
1995-2005: Organic growth within Orifarm Health Access to the rest of the Nordic countries and Orifarm Healthcare starts.
2006: Acquisition of Pharma Western, Germany (Orifarm Health Access).
2008-2010: Profit focus and split of Orifarm Trade and Orifarm Healthcare + establishment of professional and international Board of Directors.
2013: Production and inbound logistics setup in the Czech Republic.
2015: Orifarm acquires Growth House Holding, including the companies Alternova, Viminco, and Pilum Pharma.
2015-2018: Entry in the Netherlands, the United Kingdom, and Austria.
2019: Orifarm acquires the company Pilatus Comparator Solutions, with activities in the U.K., Germany, and the U.S.
2020: Acquisition from Takeda. The acquisition includes more than 100 pharmaceuticals and dietary supplements, as well as approximately 600 employees.
2020: To ensure Orifarm remains family-owned in the future, the next step of the succession is completed, as Birgitte and Hans Bøgh-Sørensen transfer further company shares to their three children. Hans Bøgh-Sørensen remains Chairman of the Board of Directors and continues to have the majority voting right.
2022: Orifarm focuses on building the foundation for further growth, as the company continues to grow into a larger, international player.
For us, achieving one goal means setting a new one. We have a history of increasing turnover, and our ambition is to keep raising the bar - for Orifarm and for our customers.
